“…Although edaravone is rather a safe agent when administered to the patients (Takumida and Anniko, 2006), its clinical application in cisplatin-induced ototoxicity remains unclear, because the problem as to whether edaravone enhances or suppresses the efficacy of cisplatin in the treatment of cancer cells remains unsettled yet. Also, since our experiment was conducted with an HEI-OC1 cell line, its conditions are not typical condition of cochlear cells as it is cultured under permissive conditions (33.8 C, 10% CO2).…”